Replay available

Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call

Nautilus Biotechnology, Inc. (NASDAQ: NAUT) Q2 2026 earnings conference call, held 2026-07-28. Replay captured from the company's public earnings webcast.

Tue, July 28, 2026 at 8:30 AMendedReplay
Nautilus Biotechnology, Inc. (NAUT) Q2 2026 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Chi-Yan Ig

Investor Relations, The Gilmartin Group

Anna Mowry

Chief Financial Officer, Nautilus Biotechnology

Parag Mallick

Co-founder and Chief Scientist, Nautilus Biotechnology

Sujal Patel

Co-founder and Chief Executive Officer, Nautilus Biotechnology

Sabud Nnamdi

Analyst, Guggenheim Partners

Dan Bredin

Analyst, TD Cowen

Replay transcript excerpt

Good day and thank you for standing by. Welcome to the Nautilus Biotechnology second quarter 2026 earnings call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised, today's conference is being recorded. I would now like to turn the conference over to your speaker today, Chi-Yan Ig with the Gilmartin Group. Please go ahead. Thank you. Earlier today, Nautilus released financial results for the quarter ended June 30, 2026. If you haven't received this news release, or if you'd like to be added to the company's distribution list, please send an email to investorrelations at nautilus.bio. Joining me today from Nautilus are Sujal Patel, co-founder and CEO, Parag Mallick, co-founder and chief scientist, and Anna Mowry, chief financial officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of the federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the press release Nautilus issued today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This confe...

More from Nautilus Biotechnology, Inc.